These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22251922)

  • 1. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
    Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study).
    Rijkaart DC; Berkhof J; van Kemenade FJ; Rozendaal L; Verheijen RH; Bulk S; Herreilers ME; Verweij WM; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 May; 126(9):2175-81. PubMed ID: 19739071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.
    Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M
    Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Hesselink AT; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij WM; Snijders PJ; Meijer CJ
    Int J Cancer; 2012 Feb; 130(3):602-10. PubMed ID: 21400507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.
    Kocken M; Berkhof J; van Kemenade FJ; Louwers JA; Zaal A; Nobbenhuis MA; Kenter G; Snijders PJ; Meijer CJ; Helmerhorst TJ
    Br J Cancer; 2012 Feb; 106(5):817-25. PubMed ID: 22333596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
    Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
    JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
    Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
    Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
    J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.
    Berkhof J; de Bruijne MC; Zielinski GD; Bulkmans NW; Rozendaal L; Snijders PJ; Verheijen RH; Meijer CJ
    Int J Cancer; 2006 Apr; 118(7):1759-68. PubMed ID: 16217759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of high-risk human papillomavirus testing in the triage of abnormal cervical cytology among Chinese younger women in Shanghai, China.
    Jiang L; Zeng Y; Li J; Wang H; Xia Y; Fang X; Zhang P
    Asian Pac J Cancer Prev; 2011; 12(11):2963-7. PubMed ID: 22393972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.